ANIP
BEARISH
$70.49
Live
ANI Pharmaceuticals, Inc. · NASDAQ
Target $110.62
(+56.9%)
$56.71
52W Range
$99.5
At a glance
Key valuation, profitability, growth, and risk metrics.
Updated Mar 14, 2026
Market cap
$1.58B
P/E
21.23
ROE
16.2%
Profit margin
8.9%
Debt/Equity
1.16
Dividend yield
N/A
AI Analysis
AI-powered fundamental assessment
Confidence
85%
ANIP's Piotroski F-Score of 4/9 indicates weak financial health, falling short of the stable threshold and signaling potential operational inefficiencies. The absence of an Altman Z-Score raises concern about bankruptcy risk, especially given a high debt/equity ratio of 1.16. Despite strong revenue growth (29.6% YoY) and solid gross margins (61.36%), the stock trades at a premium to its intrinsic value, with a current price of $70.49 versus a Graham Number of $43.90 and intrinsic value of $23.24. Insider selling activity totaling $3.39M in the last six months further undermines confidence, while technical trends remain bearish. Analysts remain optimistic with a $110.62 target, but this may reflect overvaluation given the underlying financial and sentiment risks.
Key Strengths
Strong revenue growth of 29.6% YoY
High gross margin of 61.36%
Solid operating margin of 11.99%
Healthy current ratio of 2.71 and quick ratio of 2.07
Positive analyst consensus with a 'buy' recommendation and $110.62 target price
Key Risks
Piotroski F-Score of 4/9 indicates weak financial health
No Altman Z-Score available, raising potential bankruptcy risk
Insider selling activity totaling $3.39M in last 6 months
Stock trades at a significant premium to Graham Number ($70.49 vs $43.90) and intrinsic value ($23.24)
Technical trend is bearish (0/100), with 6-month return of -27.9%
AI Fair Value Estimate
Based on comprehensive analysis
$43.9
-37.7% below current price
Performance Snowflake
Multi-dimensional analysis across 5 key categories
Overall
41
Moderate
30
75
60
40
0
AI Verdict
neutral
Key drivers: Strong revenue growth and margins, High valuation relative to intrinsic value, Weak Piotroski F-Score, Bearish insider activity, Lack of Altman Z-Score
Confidence
80%
Value
30/100
Stock trades at a substantial premium to Graham Number and intrinsic value, suggesting overvaluation unless sustained high growth is confirmed.
Positives
- P/E of 21.23 is below sector average of 164.77
- Price/Sales of 1.79 is reasonable for a growth stock
Watchpoints
- Current price ($70.49) is 59% above Graham Number ($43.90)
- Intrinsic value estimate ($23.24) is significantly below current price
- Forward P/E of 6.82 is misleading due to likely one-time earnings boost
Future
75/100
High growth expectations are priced in, but lack of earnings data and forward guidance raises uncertainty about sustainability.
Positives
- 29.6% YoY revenue growth indicates strong top-line momentum
- Forward P/E of 6.82 implies high earnings expectations
Watchpoints
- No earnings growth data available for YoY or Q/Q
- PEG ratio unavailable, limiting growth-adjusted valuation
Past
60/100
Historical performance has been strong, but recent technical trends suggest weakening momentum.
Positives
- 5-year return of +113.5% reflects strong historical performance
- 1-year return of +14.7% shows resilience despite recent pullback
Watchpoints
- 6-month return of -27.9% indicates recent bearish momentum
- 1-month and 1-week returns show continued downward pressure
Health
40/100
Despite liquidity strength, the low Piotroski score and missing Altman Z-Score indicate underlying financial fragility.
Positives
- Current ratio of 2.71 and quick ratio of 2.07 indicate strong liquidity
- Operating margin of 11.99% is healthy
Watchpoints
- Piotroski F-Score of 4/9 signals weak financial health
- Debt/Equity ratio of 1.16 is elevated for a healthcare firm
- No Altman Z-Score available, raising distress risk
Dividend
0/100
No dividend policy exists, which is typical for growth-stage biopharma firms but limits income appeal.
Positives
No standout positives identified.
Watchpoints
- No dividend yield or payout ratio
- Dividend Strength score of 0/100
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Current Price
$70.49
Analyst Target
$110.62
Upside/Downside
+56.9%
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for ANIP and closest competitors.
Updated 2026-03-13
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
ANIP
ANI Pharmaceuticals, Inc.
Primary
|
+113.5% | +73.9% | +14.7% | -27.9% | -7.5% | -4.8% |
|
IMCR
Immunocore Holdings plc
Peer
|
-3.6% | -38.5% | +20.3% | -4.2% | -4.5% | +0.7% |
|
NBTX
Nanobiotix S.A.
Peer
|
+91.8% | +705.8% | +855.9% | +12.8% | -6.4% | +5.6% |
|
AGIO
Agios Pharmaceuticals, Inc.
Peer
|
-46.7% | +21.9% | -10.4% | -24.3% | +0.5% | +1.4% |
|
UFPT
UFP Technologies, Inc.
Peer
|
+289.1% | +40.8% | -5.7% | -1.3% | +5.3% | +1.4% |
ANI
ANI Pharmaceuticals, Inc.
Primary
5Y
+113.5%
3Y
+73.9%
1Y
+14.7%
6M
-27.9%
1M
-7.5%
1W
-4.8%
IMC
Immunocore Holdings plc
Peer
5Y
-3.6%
3Y
-38.5%
1Y
+20.3%
6M
-4.2%
1M
-4.5%
1W
+0.7%
NBT
Nanobiotix S.A.
Peer
5Y
+91.8%
3Y
+705.8%
1Y
+855.9%
6M
+12.8%
1M
-6.4%
1W
+5.6%
AGI
Agios Pharmaceuticals, Inc.
Peer
5Y
-46.7%
3Y
+21.9%
1Y
-10.4%
6M
-24.3%
1M
+0.5%
1W
+1.4%
UFP
UFP Technologies, Inc.
Peer
5Y
+289.1%
3Y
+40.8%
1Y
-5.7%
6M
-1.3%
1M
+5.3%
1W
+1.4%
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Historical data shows last 12 quarters (3 years)
Valuation Metrics
Key valuation ratios and pricing indicators
P/E Ratio
21.23
Forward P/E
6.82
PEG Ratio
N/A
P/B Ratio
2.73
P/S Ratio
1.79
EV/Revenue
2.04
EV/EBITDA
10.33
Market Cap
$1.58B
Profitability
Profit margins and return metrics
Profit Margin
8.87%
Operating Margin
11.99%
Gross Margin
61.36%
ROE
16.16%
ROA
3.82%
Growth
Revenue and earnings growth rates
Revenue Growth
+29.6%
Earnings Growth
N/A
Q/Q Revenue Growth
N/A
Q/Q Earnings Growth
N/A
Financial Health
Balance sheet strength and liquidity metrics
Debt/Equity
1.16
Moderate
Current Ratio
2.71
Strong
Quick Ratio
2.07
Excellent
Cash/Share
$14.12
Healthcare Sector Comparison
Comparing ANIP against 560 companies in the Healthcare sector
(34 bullish, 167 neutral, 359 bearish)
P/E Ratio
21.23
This Stock
vs
75.44
Sector Avg
-71.9%
(Discount)
Return on Equity (ROE)
16.16%
This Stock
vs
-88.14%
Sector Avg
-118.3%
(Below Avg)
Profit Margin
8.87%
This Stock
vs
-16.28%
Sector Avg
-154.5%
(Weaker)
Debt to Equity
1.16
This Stock
vs
2.66
Sector Avg
-56.4%
(Less Debt)
Revenue Growth
29.6%
This Stock
vs
124.04%
Sector Avg
-76.1%
(Slower)
Current Ratio
2.71
This Stock
vs
4.47
Sector Avg
-39.5%
(Weaker)
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
ANIP
ANI Pharmaceuticals, Inc.
|
BEARISH | $1.58B | 21.23 | 16.2% | 8.9% | $70.49 | |
|
IMCR
Immunocore Holdings plc
|
BEARISH | $1.57B | - | -9.6% | -8.9% | $31.05 | Compare |
|
NBTX
Nanobiotix S.A.
|
BEARISH | $1.54B | - | -% | -73.5% | $31.83 | Compare |
|
AGIO
Agios Pharmaceuticals, Inc.
|
BEARISH | $1.63B | - | -30.2% | -% | $27.85 | Compare |
|
UFPT
UFP Technologies, Inc.
|
NEUTRAL | $1.53B | 22.71 | 17.8% | 11.3% | $198.68 | Compare |
ANIP
ANI Pharmaceuticals, Inc.
BEARISH
Mkt Cap
$1.6B
P/E
21.2
ROE
16.2%
Price
$70.49
Recent Insider Trading
Insider buy and sell transactions from the last 6 months
| Date | Insider | Position | Transaction | Shares | Value |
|---|---|---|---|---|---|
| 2026-03-09 | MUTZ CHRISTOPHER | Officer | Sale | 5,723 | $424,617 |
| 2026-03-09 | DAVIS KRISTA | Officer | Sale | 6,572 | $488,474 |
| 2026-03-05 | CAREY STEPHEN P. | Chief Financial Officer | Sale | 7,312 | $552,031 |
| 2026-03-05 | CAREY STEPHEN P. | Chief Financial Officer | Option Exercise | 3,312 | $163,977 |
| 2026-03-03 | WALSH PATRICK D | Director | Sale | 6,000 | $445,380 |
| 2026-03-03 | GUTWERG ORI | Officer | Sale | 2,060 | $157,590 |
| 2026-03-02 | MUTZ CHRISTOPHER | Officer | Sale | 417 | $30,858 |
| 2026-02-26 | CAREY STEPHEN P. | Chief Financial Officer | Stock Award | 22,233 | $1,715,276 |
| 2026-02-26 | LALWANI NIKHIL SURESH | Chief Executive Officer | Stock Award | 75,592 | $5,831,923 |
| 2026-02-26 | GUTWERG ORI | Officer | Stock Award | 12,969 | $1,000,558 |
| 2026-02-26 | MUTZ CHRISTOPHER | Officer | Stock Award | 21,306 | $1,643,758 |
| 2026-02-26 | SHANMUGAM MUTHUSAMY | Officer and Director | Stock Award | 11,116 | $857,599 |
| 2026-02-26 | GASSERT CHAD | Officer | Stock Award | 11,116 | $857,599 |
| 2026-02-26 | COOK MEREDITH | General Counsel | Stock Award | 13,895 | $1,071,999 |
| 2026-02-26 | ROWLAND THOMAS ANDREW | Officer | Stock Award | 6,021 | $464,520 |
MUTZ CHRISTOPHER
Officer
2026-03-09
5,723 shares
·
$424,617
DAVIS KRISTA
Officer
2026-03-09
6,572 shares
·
$488,474
CAREY STEPHEN P.
Chief Financial Officer
2026-03-05
7,312 shares
·
$552,031
CAREY STEPHEN P.
Chief Financial Officer
2026-03-05
3,312 shares
·
$163,977
WALSH PATRICK D
Director
2026-03-03
6,000 shares
·
$445,380
GUTWERG ORI
Officer
2026-03-03
2,060 shares
·
$157,590
MUTZ CHRISTOPHER
Officer
2026-03-02
417 shares
·
$30,858
CAREY STEPHEN P.
Chief Financial Officer
2026-02-26
22,233 shares
·
$1,715,276
LALWANI NIKHIL SURESH
Chief Executive Officer
2026-02-26
75,592 shares
·
$5,831,923
GUTWERG ORI
Officer
2026-02-26
12,969 shares
·
$1,000,558
MUTZ CHRISTOPHER
Officer
2026-02-26
21,306 shares
·
$1,643,758
SHANMUGAM MUTHUSAMY
Officer and Director
2026-02-26
11,116 shares
·
$857,599
GASSERT CHAD
Officer
2026-02-26
11,116 shares
·
$857,599
COOK MEREDITH
General Counsel
2026-02-26
13,895 shares
·
$1,071,999
ROWLAND THOMAS ANDREW
Officer
2026-02-26
6,021 shares
·
$464,520
Insider transactions can signal confidence or concerns about company prospects
Wall Street Analysts
Professional analyst ratings and price targets
Consensus
BUY
8 analysts
Guggenheim
2026-01-16
Buy
Buy
Barclays
2025-12-09
Overweight
Guggenheim
2025-11-10
Buy
Buy
Truist Securities
2025-10-09
Hold
Hold
JP Morgan
2025-09-24
Overweight
Overweight
HC Wainwright & Co.
2025-09-17
Buy
Buy
Past News Coverage
Recent headlines mentioning ANIP from our newsroom.
Newest → oldest
No matching news yet.